Nuformix (LON:NFX) Trading Up 5.1% – Still a Buy?

Nuformix plc (LON:NFX)’s stock price traded up 5.1% during mid-day trading on Thursday . The company traded as high as GBX 0.31 and last traded at GBX 0.31. 10,830,912 shares were traded during mid-day trading, a decline of 43% from the average session volume of 18,889,604 shares. The stock had previously closed at GBX 0.30.

Nuformix Stock Down 3.0%

The business’s fifty day moving average is GBX 0.28 and its two-hundred day moving average is GBX 0.21. The stock has a market capitalization of £6.12 million, a PE ratio of -0.74 and a beta of 1.22.

Nuformix Company Profile

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.